Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130260 · ClinicalTrials.gov registry record · Phase 3
Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease
A Phase 3 study, sponsored by Nabi Biopharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 99
- Enrollment target
NCT00130260 is a Phase 3 study that was terminated before completion, run by Nabi Biopharmaceuticals. The registered enrollment target is 99 participants.
The verdict
NCT00130260, a Phase 3 study, was terminated before completion, sponsored by Nabi Biopharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 99 participants
- Enrollment target
Study Summary
This study is a continued evaluation of the immune response to StaphVAX , a Staphylococcus aureus type 5 and 8 capsular polysaccharide conjugate vaccine, in end-stage renal disease patients, by giving a 3rd and 4th dose to a subset of the participants in the previous efficacy trial. Participants continue to receive the vaccine or placebo in a blinded manner, and are also randomly assigned to 1 of 2 different intervals between the doses. The immunogenicity is measured by the antibodies in the blood, and typical vaccine safety information is also collected.
Interventions
- BIOLOGICAL placebo
- BIOLOGICAL Staph aureus types 5 and 8 conjugate vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2005-08 |
| Est. Completion | 2006-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130260
The ClinicalTrials.gov registry entry for NCT00130260 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nabi Biopharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00130260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00130260 about?
NCT00130260 is a clinical study titled "Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease". This study is a continued evaluation of the immune response to StaphVAX , a Staphylococcus aureus type 5 and 8 capsular polysaccharide conjugate vaccine, in end-stage renal disease patients, by giving a 3rd and 4th dose to a subset of the participants in the previous efficacy trial. Participants con...
What is the current status of trial NCT00130260?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 99 participants. The study started on 2005-08. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00130260?
The interventions under investigation include: placebo (BIOLOGICAL), Staph aureus types 5 and 8 conjugate vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00130260?
This trial is sponsored by Nabi Biopharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.